Generated by AI
Insmed Incorporated is a global biopharmaceutical company that develops and commercializes therapies for patients with serious and rare diseases. Its current portfolio includes an approved treatment for Mycobacterium avium complex lung disease, along with clinical-stage programs focused on pulmonary and inflammatory conditions. The company’s pipeline emphasizes innovative approaches such as oral therapies and inhaled medicines designed to address difficult-to-treat respiratory disorders. Insmed also conducts research across multiple scientific platforms, including protein engineering and other advanced drug-development technologies. Headquartered in Bridgewater, New Jersey, Insmed serves patients and healthcare providers in the United States, Europe, Japan, and other international markets, positioning itself as a specialist in rare-disease and specialty respiratory treatment.
Website700 US Highway 202/206
Bridgewater, NJ, 08807
United States
The latest articles about INSM.
Technical indicators show Insmed stock poised to gain 30% from current levels.
Summary of Nov 16's posts. Generated by AI.
Summary of Oct 29's posts. Generated by AI.
Summary of Sep 6's posts. Generated by AI.
Summary of Oct 29's posts. Generated by AI.
Investors talking about INSM also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.